Farmitalia Carlo Erba SPA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Farmitalia Carlo Erba SPA
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.